[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:hepatocellular-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":307,"states":337},"Hepatocellular Carcinoma",188,157,[8,16,23,30,36,42,48,55,61,67,73,79,85,91,97,103,109,115,120,127,133,139,145,151,156,162,167,173,180,186,192,198,203,208,213,219,225,231,237,243,249,255,261,267,273,279,285,291,297,302],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05669339","AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma",[12],"Phase 2","RECRUITING","2026-08-26T02:17:14.343713Z","2026-07-05T05:32:16.808794Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07042919","Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer",[20],"Phase 1\u002FPhase 2","2026-08-26T02:15:37.042762Z","2026-07-05T05:32:16.731900Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06921785","Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma",[27],"Phase 3","2026-08-26T02:19:05.360997Z","2026-07-05T05:32:16.703088Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07219459","Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure",[12],"2026-08-26T02:16:06.684983Z","2026-07-05T03:45:20.250006Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT04864054","GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC",[20],"2026-08-26T02:17:40.683658Z","2026-06-16T05:54:07.907593Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT05620771","Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk",[12],"2026-08-26T02:16:10.529598Z","2026-05-29T15:36:40.166071Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":53,"content_modified":54},"NCT07176650","Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma",[52],"Phase 1","2026-08-26T02:17:18.747857Z","2026-05-05T02:43:29.700236Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT05366829","Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma",[12],"2026-08-26T02:16:12.203827Z","2026-05-05T02:43:29.682232Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT07226869","Computer Guided Microwave Liver Ablation",[],"2026-08-26T02:17:56.243868Z","2026-05-05T02:43:29.651323Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06914648","The Dragon PLC Trial (DRAGON-PLC)",[],"2026-08-26T02:17:49.709549Z","2026-05-05T02:43:29.586465Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06600321","A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma",[52],"2026-08-26T02:17:32.059863Z","2026-05-05T02:43:29.538970Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT04472767","Cabozantinib Combined With Ipilimumab\u002FNivolumab and TACE in Patients With Hepatocellular Carcinoma",[12],"2026-08-26T02:16:48.735701Z","2026-05-05T02:43:29.526698Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT05201404","Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis",[27],"2026-08-26T02:17:04.346841Z","2026-05-05T02:43:29.480229Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT03897543","ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma",[20],"2026-08-26T02:15:33.331531Z","2026-05-05T02:43:29.464631Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT07174570","Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer",[12],"2026-08-26T02:17:01.714035Z","2026-05-05T02:43:29.384530Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT05901519","A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma",[12],"2026-08-26T02:18:16.220328Z","2026-05-05T02:43:29.295756Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT05797805","A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma",[20],"2026-08-26T02:17:11.311767Z","2026-05-05T02:43:29.284306Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":46,"content_modified":119},"NCT07227012","Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.",[20],"2026-05-05T02:43:29.190461Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":125,"content_modified":126},"NCT06109272","A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)",[124],"Phase 2\u002FPhase 3","2026-08-26T02:18:49.989941Z","2026-05-05T02:43:29.060831Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT05488522","SBRT With Atezo\u002FBev for HCC",[52],"2026-08-26T02:19:17.380174Z","2026-05-05T02:43:28.857495Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT07166406","Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial",[27],"2026-08-26T02:17:48.768272Z","2026-05-05T02:43:28.809147Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT05440708","A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma",[20],"2026-08-26T02:16:59.895916Z","2026-05-05T02:43:28.725459Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT03942328","Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer",[20],"2026-08-26T02:18:17.007929Z","2026-05-05T02:43:28.654499Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":131,"content_modified":155},"NCT03259867","Combination of TATE and PD-1 Inhibitor in Liver Cancer",[12],"2026-05-05T02:43:28.641356Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT06728293","Effect of the HCC Liver-Link Intervention",[],"2026-08-26T02:15:26.669629Z","2026-05-05T02:43:28.512348Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":113,"content_modified":166},"NCT07118202","TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma",[],"2026-05-05T02:43:28.367312Z",{"nct_id":168,"title":169,"phases":170,"status":13,"updated_at":171,"content_modified":172},"NCT06526338","Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone",[12],"2026-08-26T02:18:38.865010Z","2026-05-05T02:43:28.345423Z",{"nct_id":174,"title":175,"phases":176,"status":13,"updated_at":178,"content_modified":179},"NCT06717919","HOPE Against Cancer Recurrence in HCC",[177],"Phase 4","2026-08-26T02:17:42.501124Z","2026-05-05T02:43:28.222453Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT05953961","90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia",[],"2026-08-26T02:18:20.384845Z","2026-05-05T02:43:28.222371Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT05701488","SIRT With Tremelimumab and Durvalumab for Resectable HCC",[52],"2026-08-03T01:58:52.019365Z","2026-05-05T02:43:28.192298Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT05223816","An Open-Label, Multiple-Center, Phase IIa\u002FIIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma",[12],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:28.162660Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":53,"content_modified":202},"NCT06007846","A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer",[124],"2026-05-05T02:43:27.996906Z",{"nct_id":204,"title":205,"phases":206,"status":13,"updated_at":53,"content_modified":207},"NCT06726161","Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC",[20],"2026-05-05T02:43:27.948834Z",{"nct_id":209,"title":210,"phases":211,"status":13,"updated_at":77,"content_modified":212},"NCT07059494","Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant",[177],"2026-05-05T02:43:27.947322Z",{"nct_id":214,"title":215,"phases":216,"status":13,"updated_at":217,"content_modified":218},"NCT06795022","First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours",[20],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:27.945446Z",{"nct_id":220,"title":221,"phases":222,"status":13,"updated_at":223,"content_modified":224},"NCT06915753","Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF\u002FFGFR Pathway Aberrations",[52],"2026-08-26T02:15:45.413021Z","2026-05-05T02:43:27.835984Z",{"nct_id":226,"title":227,"phases":228,"status":13,"updated_at":229,"content_modified":230},"NCT07291076","A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)",[20],"2026-08-26T02:17:45.190188Z","2026-05-05T02:43:27.798790Z",{"nct_id":232,"title":233,"phases":234,"status":13,"updated_at":235,"content_modified":236},"NCT05003895","GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies",[52],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:27.669007Z",{"nct_id":238,"title":239,"phases":240,"status":13,"updated_at":241,"content_modified":242},"NCT05842174","Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma",[20],"2026-08-26T02:15:40.343619Z","2026-05-05T02:43:27.658011Z",{"nct_id":244,"title":245,"phases":246,"status":13,"updated_at":247,"content_modified":248},"NCT07489976","IIT2025-03-YANG-LIFT-HCC",[12],"2026-08-26T02:17:25.718160Z","2026-05-05T02:43:27.635955Z",{"nct_id":250,"title":251,"phases":252,"status":13,"updated_at":253,"content_modified":254},"NCT06852820","68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)",[12],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:27.635884Z",{"nct_id":256,"title":257,"phases":258,"status":13,"updated_at":259,"content_modified":260},"NCT06789757","The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)",[12],"2026-08-26T02:16:11.347936Z","2026-05-05T02:43:27.626651Z",{"nct_id":262,"title":263,"phases":264,"status":13,"updated_at":265,"content_modified":266},"NCT05417932","A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma",[20],"2026-08-26T02:18:00.873391Z","2026-05-05T02:43:27.511518Z",{"nct_id":268,"title":269,"phases":270,"status":13,"updated_at":271,"content_modified":272},"NCT07075120","Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer",[52],"2026-08-26T02:19:23.493898Z","2026-05-05T02:43:27.509471Z",{"nct_id":274,"title":275,"phases":276,"status":13,"updated_at":277,"content_modified":278},"NCT06789848","Ligufalimab and Cadonilimab in Advanced Liver Cancers",[12],"2026-08-26T02:19:14.560989Z","2026-05-05T02:43:27.446916Z",{"nct_id":280,"title":281,"phases":282,"status":13,"updated_at":283,"content_modified":284},"NCT05185505","Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria",[177],"2026-08-26T02:18:32.765187Z","2026-05-05T02:43:27.420071Z",{"nct_id":286,"title":287,"phases":288,"status":13,"updated_at":289,"content_modified":290},"NCT06553885","Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC",[12],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:27.394981Z",{"nct_id":292,"title":293,"phases":294,"status":13,"updated_at":295,"content_modified":296},"NCT05096715","Atezolizumab+Bevacizumab+SBRT in Unresectable HCC",[52],"2026-08-26T02:16:41.943926Z","2026-05-05T02:43:27.321203Z",{"nct_id":298,"title":299,"phases":300,"status":13,"updated_at":277,"content_modified":301},"NCT05168163","Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer",[12],"2026-05-05T02:43:27.258385Z",{"nct_id":303,"title":304,"phases":305,"status":13,"updated_at":101,"content_modified":306},"NCT04430452","Durvalumab With\u002FWithout Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma",[12],"2026-05-05T02:43:26.898350Z",[308,312,316,319,323,326,330,333],{"biomarker":309,"count":310,"slug":311},"Glypican-3",9,"glypican-3",{"biomarker":313,"count":314,"slug":315},"Hepatitis B Infection",7,"hepatitis-b-infection",{"biomarker":317,"count":314,"slug":318},"MSI1 Gene","msi1-gene",{"biomarker":320,"count":321,"slug":322},"MRC1 wt Allele",5,"mrc1-wt-allele",{"biomarker":324,"count":321,"slug":325},"Programmed Cell Death 1 Ligand 1","programmed-cell-death-1-ligand-1",{"biomarker":327,"count":328,"slug":329},"Alpha-Fetoprotein",4,"alpha-fetoprotein",{"biomarker":331,"count":328,"slug":332},"Hepatitis C Infection","hepatitis-c-infection",{"biomarker":334,"count":335,"slug":336},"CTNNB1 Gene",3,"ctnnb1-gene",[338,342,346,350,354,358,362,366,370,374,378,382,385,389,392,396,399,402,405,409,412,416,419,423],{"state":339,"count":340,"slug":341},"California",83,"california",{"state":343,"count":344,"slug":345},"Texas",72,"texas",{"state":347,"count":348,"slug":349},"New York",47,"new-york",{"state":351,"count":352,"slug":353},"Florida",38,"florida",{"state":355,"count":356,"slug":357},"Pennsylvania",35,"pennsylvania",{"state":359,"count":360,"slug":361},"Michigan",33,"michigan",{"state":363,"count":364,"slug":365},"Ohio",32,"ohio",{"state":367,"count":368,"slug":369},"Illinois",28,"illinois",{"state":371,"count":372,"slug":373},"Massachusetts",26,"massachusetts",{"state":375,"count":376,"slug":377},"Minnesota",23,"minnesota",{"state":379,"count":380,"slug":381},"Arizona",22,"arizona",{"state":383,"count":380,"slug":384},"Virginia","virginia",{"state":386,"count":387,"slug":388},"Tennessee",21,"tennessee",{"state":390,"count":387,"slug":391},"Washington","washington",{"state":393,"count":394,"slug":395},"Colorado",18,"colorado",{"state":397,"count":394,"slug":398},"Georgia","georgia",{"state":400,"count":394,"slug":401},"Maryland","maryland",{"state":403,"count":394,"slug":404},"Missouri","missouri",{"state":406,"count":407,"slug":408},"North Carolina",16,"north-carolina",{"state":410,"count":407,"slug":411},"Oregon","oregon",{"state":413,"count":414,"slug":415},"New Jersey",13,"new-jersey",{"state":417,"count":414,"slug":418},"Wisconsin","wisconsin",{"state":420,"count":421,"slug":422},"Connecticut",12,"connecticut",{"state":424,"count":425,"slug":426},"Alabama",11,"alabama"]